title: Serological screening for sexually transmitted infections in pregnancy: is there any value in re-screening for HIV and syphilis at the time of delivery?
abstract: OBJECTIVE
  The aim of this study was to assess the prevalence of syphilis, human immunodeficiency virus (HIV), and hepatitis B virus (HBV) infections in women at the time of delivery, and to determine the seroconversion rates for syphilis and HIV infections from initial booking visit to delivery.
  
  
  METHODS
  The labour ward of a typical tertiary hospital in a developing country and serving an indigent African population.
  
  
  METHODS
  Four hundred and eighteen women presenting in labour were randomly selected and informed consent obtained for serological testing for syphilis and HBV infections in umbilical cord blood samples. The specimens were then given a study number, the gestational ages recorded and anonymously tested for HIV infection.
  
  
  RESULTS
  Of the 191 women who had antenatal care, 13 (6.8%) were HIV antibody positive at the initial "booking" visit. An additional 4 were found to be HIV antibody positive at the time of delivery resulting in a seroconversion rate of 2.2%. The seroconversion rate for syphilis at the time of delivery was 2.7%. Hepatitis B surface antigens were detected in only 2 women, one of whom was antigen positive.
  
  
  CONCLUSIONS
  The high seroconversion rates for both syphilis and HIV infection in pregnancy justifies re-screening for these conditions in endemic areas such as ours.
authors.affiliation: Department of Obstetrics and Gynaecology, University of Natal, Durban, South Africa.
authors.forename: D C
authors.initials: DC
authors.lastname: Qolohle
authors.forename: A A
authors.initials: AA
authors.lastname: Hoosen
authors.forename: J
authors.initials: J
authors.lastname: Moodley
authors.forename: A N
authors.initials: AN
authors.lastname: Smith
authors.forename: K P
authors.initials: KP
authors.lastname: Mlisana
mesh_terms: D036861:Delivery, Obstetric; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D015483:HIV Antibodies / Q000032:analysis; D006679:HIV Seropositivity / Q000453:epidemiology*; D015528:HIV Seroprevalence; D006509:Hepatitis B / Q000453:epidemiology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D008403:Mass Screening; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology*; D011295:Prenatal Care; D015995:Prevalence; D013587:Syphilis / Q000453:epidemiology*; D013590:Syphilis, Congenital / Q000517:prevention & control; D013997:Time Factors
chemical_list: D015483:HIV Antibodies; D006514:Hepatitis B Surface Antigens